The Omic Insights on Unfolding Saga of COVID-19 DOI Creative Commons

Arvinpreet Kaur,

Mehak Chopra,

Mahak Bhushan

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: Oct. 20, 2021

The year 2019 has seen an emergence of the novel coronavirus named severe acute respiratory syndrome 2 (SARS-CoV-2) causing disease (COVID-19). Since onset pandemic, biological and interdisciplinary research is being carried out across world at a rapid pace to beat pandemic. There increased need comprehensively understand various aspects virus from detection treatment options including drugs vaccines for effective global management disease. In this review, we summarize salient findings pertaining SARS-CoV-2 biology, symptoms, hosts, epidemiology, genome, its emerging variants, viral diagnostics, host-pathogen interactions, alternative antiviral strategies application machine learning heuristics artificial intelligence COVID-19 future pandemics.

Language: Английский

False Positivity of Anti-SARS-CoV-2 Antibodies in Patients with Acute Tropical Diseases in Thailand DOI Creative Commons
Viravarn Luvira, Pornsawan Leaungwutiwong,

Narin Thippornchai

et al.

Tropical Medicine and Infectious Disease, Journal Year: 2022, Volume and Issue: 7(7), P. 132 - 132

Published: July 12, 2022

Serology remains a useful indirect method of diagnosing tropical diseases, especially in dengue infection. However, the current literature regarding cross-reactivity between SARS-CoV-2 and serology is limited revealed conflicting results. As means to uncover relevant serological insight involving antibody classes against cross-reactivity, anti-SARS-CoV-2 IgA, IgM, IgG ELISA, based on spike nucleocapsid proteins, were selected for fever-presenting disease patient investigation. The study was conducted at Faculty Tropical Medicine during March December 2021. data source comprised (i) 170 non-COVID-19 sera from 140 adults children presenting with acute undifferentiated febrile illness 30 healthy volunteers, (ii) 31 COVID-19 17 RT-PCR-confirmed patients. Among samples, 27 false positives (15.9%), which cross-reactive detected 18 (10.6%), 9 (5.3%), 3 (1.8%) cases, respectively. Interestingly, one case exhibited both IgA IgM positivity, while two cases positivity. positivity rate reported infection (11.3% 5%) other diseases (16.7% 13.3%). urea dissociation applied mitigate resulted significantly decreased ELISA-based true positives. In conclusion, analysis patients different showed that high thus potentially limits assay utility areas.

Language: Английский

Citations

12
Diagnostic Performance of Seven Commercial COVID-19 Serology Tests Available in South America DOI Creative Commons
Ismar A. Rivera‐Olivero, Aquiles R. Henríquez-Trujillo, Nikolaos C. Kyriakidis

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2022, Volume and Issue: 12

Published: Feb. 18, 2022

Background Although RT-qPCR remains the gold-standard for COVID-19 diagnosis, anti-SARS-CoV-2 serology-based assays have been widely used during 2020 as an alternative individual and mass testing, are currently seroprevalence studies. Objective To study clinical performance of seven commercial serological tests diagnosis available in South America. Methods We conducted a blind evaluation five lateral-flow immunoassays (LFIA) two enzyme-linked immunosorbent (ELISAs) detecting antibodies. Results found no statistically significant differences among ELISA kits LFIAs IgG sensitivity (values ranging from 76.4% to 83.5%) specificity (100% assays). For IgM, significantly higher samples collected 15 days after first time positive test, with values 47.1% 88.2%; moreover, varied 85% 100%, but only LFIA brand 100% had lowest sensitivity. Conclusion The diagnostic was acceptable brands tested detection screening purposes. On other hand, our results show lack accuracy IgM tool SARS-CoV-2 acute-phase infection diagnosis.

Language: Английский

Citations

10
Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis DOI Creative Commons
John P. A. Ioannidis, Despina G. Contopoulos‐Ioannidis

International Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 134, P. 160 - 167

Published: June 15, 2023

To assess the evidence on presence of antibodies cross-reactive with SARS-CoV-2 antigens in prepandemic samples from African populations.

Language: Английский

Citations

6
Coinfection and cross-reaction of dengue and COVID-19: a case series analysis DOI Creative Commons
Maria Emilia Avelar Machado, Elza Kimura

Revista da Sociedade Brasileira de Medicina Tropical, Journal Year: 2022, Volume and Issue: 55

Published: Jan. 1, 2022

The risk of possible cross-reactions between serological tests, together with the clinical similarities dengue fever and COVID-19, can delay diagnosis increase both COVID-19 transmission worsening. present study aimed to determine possibility among rapid tests based on symptoms.Patients confirmed by RT-PCR criteria for diagnosing dengue, were recruited consecutively September 2020 August 2021 underwent immunochromatographic diagnostic (RID) AgNS1, IgM, IgG. Patients who tested positive acute-phase IgM AgNS1 a follow-up test after 12-30 days confirmation.A total 43 patients included, 38 whom required hospital admission, 8 received intensive care. Seven RID comprising 2 NS1 (coinfection), one reactive IgG three not (false-positive), due previous infection. Two 3 coinfection died. Fever, myalgia, headache, cough most common symptoms, while lymphopenia was prevalent laboratory finding.Cross-reactivity found in only another patients, two died severe manifestations.

Language: Английский

Citations

9
SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes DOI Creative Commons
Evelin Garay, Héctor Serrano-Coll, Ricardo Rivero

et al.

Transactions of the Royal Society of Tropical Medicine and Hygiene, Journal Year: 2021, Volume and Issue: 116(2), P. 139 - 147

Published: June 11, 2021

Serological evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an alternative that allows us to determine the prevalence and dynamics this infection in populations. The goal study was clinical sociodemographic SARS-CoV-2 a region Colombian Caribbean. Between July November 2020, cross-sectional observational carried out Córdoba, located northeast Colombia Caribbean area. Eight municipalities with largest populations were chosen 2564 blood samples taken. A commercial enzyme-linked immunosorbent assay used recombinant protein antigen N SARS-CoV-2. people included asked for data, which analysed by statistical methods. seroprevalence 40.8% obtained Córdoba region. In bivariate analysis, no differences observed seropositivity against gender or age range (p>0.05). Higher found low socio-economic status symptomatic patients (p<0.0001). total 30.7% asymptomatic seropositive SARS-CoV-2, could be linked spread infection. multivariate seroconversion related poverty manifestations such as anosmia ageusia (p<0.05). high due widespread population. relationship between suggests higher exposure risk virus caused informal economic activities low-income groups. Clinical predictors new emergent coronavirus.

Language: Английский

Citations

10
Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama DOI Creative Commons
Carolina De La Guardia, Giselle Rangel, Alcibiades E. Villarreal

et al.

PLoS ONE, Journal Year: 2021, Volume and Issue: 16(9), P. e0257351 - e0257351

Published: Sept. 14, 2021

COVID-19 is the name of acute respiratory disease caused by new coronavirus SARS-CoV-2, a close relative those that severe outbreaks SARS and MERS several years ago. Since first appearance on December 2019, pandemic has cause extremely high levels mortality, morbidity, global economic breakdown, consequent human suffering. The main diagnostic test for confirmation symptomatic individuals detection viral RNA reverse transcriptase-quantitative real time PCR (RT-PCR). Additionally, serology techniques, such as ELISA are useful to measure antibodies produced in humans after contact with virus, well direct presence antigens. In this study we aim assemble evaluate four assays IgG or IgM specific Spike protein patients, using either full recombinant SARS-CoV-2 fragment corresponding receptor binding domain. As control, analyzed group pre-pandemic serum samples obtained before 2017. Strong reactivity was observed against both A few displayed OD values, suggesting possibility some cross reactivity. All show very good repeatability, intra- inter-assay. Receiver operating characteristic analysis allowed definition cutoffs evaluation performance each estimation area under curve. This parameter all tests (AUC range: 0.98-0.99). Multiple comparisons between revealed no significant difference other (P values: 0.24-0.95). Our results antigens effective detect antibodies, sensitivity (range 0.92-0.99), specificity 0.93-0.97) congruence RT-PCR (Cohen´s Kappa range 0.87-0.93). These will allow health authorities have tool estimate seroprevalence, order manage improve sanitary situation virus.

Language: Английский

Citations

10
Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand DOI Creative Commons
Yifan Li, Mélanie Merbah, Suzanne E. Wollen-Roberts

et al.

Emerging infectious diseases, Journal Year: 2022, Volume and Issue: 28(11), P. 2214 - 2225

Published: Oct. 26, 2022

Abstract Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, 2,250 persons in 4 countries Africa (Kenya, Nigeria, Tanzania, Uganda) Thailand, including living with HIV-1. detected IgG spike (S) subunit 2 protein 1.8% of participants. Profiling against 23 coronavirus antigens revealed that S, 2, or 1 proteins were significantly more frequent than receptor-binding domain, S-Trimer, nucleocapsid (p<0.0001). observed similar without Among all tested, SARS-CoV-2, SARS-CoV-1, Middle East respiratory syndrome antibody much higher participants Thailand (p<0.01). noted less pronounced differences for endemic coronaviruses. Serosurveys could vaccine monoclonal distribution across global populations.

Language: Английский

Citations

7
Production of antigens expressed in Nicotiana benthamiana plant and Escherichia coli for the SARS-CoV-2 IgG antibody detection by ELISA DOI
Matheus Bernardes Torres Fogaça, Leonardo Lopes-Luz, Djairo Pastor Saavedra

et al.

Journal of Virological Methods, Journal Year: 2024, Volume and Issue: 329, P. 114969 - 114969

Published: June 2, 2024

Language: Английский

Citations

1
Detection of Anti-Nucleocapsid Antibody in COVID-19 Patients in Bangladesh Is not Correlated with Previous Dengue Infection DOI Creative Commons
Simon D. Lytton, Mahmuda Yeasmin, Asish Kumar Ghosh

et al.

Pathogens, Journal Year: 2021, Volume and Issue: 10(6), P. 637 - 637

Published: May 22, 2021

The assessment of antibody responses to severe acute respiratory syndrome coronavirus-2 is potentially confounded by exposures flaviviruses. aims the present research were determine whether anti-dengue antibodies affect viral load and detection anti-coronavirus nucleocapsid (N)-protein in coronavirus infectious disease 2019 (COVID-19) Bangladesh.Viral RNA was evaluated swab specimens from 115 COVID-19 patients real-time reverse transcription polymerase chain reaction (rT-PCR). anti-N-protein antibodies, virus E-protein dengue non-structural protein-1 determined serum patients, 30 fever pre-COVID-19 pandemic nine normal controls ELISA.The concentrations nasopharyngeal; Ct median (95% CI); 22 (21.9-23.3) significantly higher than oropharyngeal swabs; 29 (27-30.5) p < 0.0001. Viral not correlated with-dengue IgG levels. anti-nucleocapsid IgA 27% positive 35% at days 1 8 post-onset symptoms versus 0% levels anti- or IgM revealed no significant correlations.Viral detected dengue-endemic regions Bangladesh, independently

Language: Английский

Citations

9
On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination DOI Creative Commons
Lorena O. Fernandes-Siqueira,

Fabiana A. P. Ferreira,

Bruna G. Sousa

et al.

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: June 20, 2022

The Covid-19 pandemic, caused by SARS-CoV-2, has resulted in over 6 million reported deaths worldwide being one of the biggest challenges world faces today. Here we present optimizations all steps an enzyme-linked immunosorbent assay (ELISA)-based test to detect IgG, IgA and IgM against trimeric spike (S) protein, receptor binding domain (RBD), N terminal nucleocapsid (N-NTD) protein SARS-CoV-2. We discuss how determine specific thresholds for antibody positivity its limitations according antigen used. applied a cohort 126 individuals from Rio de Janeiro, Brazil, consisting 23 PCR-positive 103 without confirmed diagnosis SARS-CoV-2 infection. To illustrate differences serological responses vaccinal immunization, 18 our before after receiving ChAdOx-1 nCoV-19 or CoronaVac vaccines. Taken together, results show that can be customized at different stages depending on application, enabling user analyze cohorts, saving time, reagents, samples. It is also valuable tool elucidating immunological consequences new viral strains monitoring vaccination coverage duration response immunization regimens.

Language: Английский

Citations

6